Oncology Corporate Profile
| 2.5000 | |
| 0.0900 |
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer.
Website: http://www.vblrx.com
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| VB-111 | anti angiogenic agent | Glioblastoma Multiforme (GBM) | III | |
| VB-111 | anti angiogenic agent | Ovarian cancer | II | |
| VB-111 | anti angiogenic agent | Thyroid cancer | II | |
| VB-111 | anti angiogenic agent | Various cancer types | I |
View additional information on product candidates here »
Follow @OBRTweets